Milestone Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Milestone Pharmaceuticals
MIST Stock  USD 2.38  0.03  1.24%   
Milestone Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Milestone Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Milestone Pharmaceuticals financial statements helps investors assess Milestone Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Milestone Pharmaceuticals' valuation are summarized below:
Market Capitalization
128.5 M
Enterprise Value Revenue
81.4416
Earnings Share
(0.67)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental ratios for Milestone Pharmaceuticals that can be evaluated and compared over time across peers in the industry. All traders should check Milestone Pharmaceuticals' last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 252.6 M in 2025. Enterprise Value is likely to gain to about 206 M in 2025

Milestone Pharmaceuticals Total Revenue

1,000,000

Check Milestone Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Milestone Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 1.1 M or Interest Income of 4.4 M, as well as many indicators such as Price To Sales Ratio of 32.97, Dividend Yield of 0.0 or PTB Ratio of 11.73. Milestone financial statements analysis is a perfect complement when working with Milestone Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Milestone Pharmaceuticals Correlation against competitors.
For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide.

Milestone Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets100.9 M75.5 M64.3 M
Slightly volatile
Other Current Liabilities2.8 M5.6 M1.8 M
Slightly volatile
Total Current Liabilities6.7 M8.1 M4.2 M
Slightly volatile
Property Plant And Equipment Net1.3 M1.6 M701.7 K
Slightly volatile
Accounts Payable3.4 M1.9 M2.1 M
Slightly volatile
Cash45 M25.3 M35.7 M
Slightly volatile
Non Current Assets Total1.3 M1.6 M701.7 K
Slightly volatile
Cash And Short Term Investments94.8 M69.7 M60.8 M
Slightly volatile
Net Receivables1.4 M1.5 M951.4 K
Slightly volatile
Common Stock Total Equity161.3 M289.7 M106 M
Slightly volatile
Common Stock Shares Outstanding38.8 M62.2 M30.4 M
Slightly volatile
Liabilities And Stockholders Equity100.9 M75.5 M64.3 M
Slightly volatile
Non Current Liabilities Total30.7 M54.2 M46.9 M
Slightly volatile
Capital Surpluse19 M18.1 M7.4 M
Slightly volatile
Other Current Assets3.5 M2.7 M1.9 M
Slightly volatile
Other Stockholder Equity97.3 M92.6 M17.7 M
Slightly volatile
Total Liabilities35.6 M62.4 M51 M
Slightly volatile
Property Plant And Equipment Gross1.4 M1.9 M756.5 K
Slightly volatile
Total Current Assets99.6 M73.9 M63.6 M
Slightly volatile
Net Working Capital92.9 M65.8 M59.4 M
Slightly volatile
Common Stock213.9 M288 M111.1 M
Slightly volatile
Property Plant Equipment3.2 M3.1 M901.3 K
Slightly volatile
Capital Stock244.3 M288 M113.4 M
Slightly volatile
Short and Long Term Debt Total57.5 M54.8 M10.8 M
Slightly volatile
Capital Lease Obligations1.5 M1.4 M887.6 K
Slightly volatile
Warrants55.5 M60.9 M50.2 M
Slightly volatile
Non Current Liabilities Other468 K426.6 K623.3 K
Slightly volatile

Milestone Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income1.1 M583 K656 K
Slightly volatile
Interest Income4.4 M4.2 M1.2 M
Slightly volatile
Depreciation And Amortization153.2 K105.8 K80.6 K
Slightly volatile
Selling General Administrative11.4 M16.7 M6.5 M
Slightly volatile
Selling And Marketing Expenses18.3 M17.4 M5.9 M
Slightly volatile
Other Operating Expenses51.1 M71.4 M31.6 M
Slightly volatile
Research Development13.6 M14.4 M17.2 M
Slightly volatile
Total Operating Expenses49 M31.1 M29 M
Slightly volatile
Reconciled Depreciation71.6 K105 K40.5 K
Slightly volatile
Total Other Income Expense Net1.1 M1.6 M696.9 K
Slightly volatile
Non Operating Income Net Other378.4 K198 K576.4 K
Slightly volatile

Milestone Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock103.5 K108.9 K28.9 M
Slightly volatile
Stock Based Compensation5.3 M5.8 M2.8 M
Slightly volatile
Begin Period Cash Flow13.1 M13.8 M29.5 M
Slightly volatile
Depreciation73.2 K105 K41.3 K
Slightly volatile
Total Cash From Financing Activities35.8 M32.1 M38 M
Very volatile
End Period Cash Flow45 M25.3 M35.7 M
Slightly volatile
Change To Netincome8.8 M8.4 M2.9 M
Slightly volatile
Change Receivables72 K110.4 K53.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.9764.5626.381
Slightly volatile
Days Sales Outstanding1.3 K1.3 K264
Slightly volatile
Stock Based Compensation To Revenue9.018.582.1723
Slightly volatile
Capex To Depreciation1.331.43.7803
Slightly volatile
EV To Sales10498.7829.5805
Slightly volatile
Payables Turnover0.230.241.0778
Slightly volatile
Sales General And Administrative To Revenue15.0614.343.6497
Slightly volatile
Research And Ddevelopement To Revenue29.3427.957.9528
Slightly volatile
Capex To Revenue0.06660.10.0616
Slightly volatile
Cash Per Share1.061.12032.0717
Pretty Stable
Days Payables Outstanding1.9 K2 K7.3 K
Very volatile
Income Quality0.960.69480.9326
Slightly volatile
Current Ratio17.049.097516.3198
Slightly volatile
Receivables Turnover0.280.323.602
Slightly volatile
Debt To Equity4.384.1680.7331
Slightly volatile
Capex Per Share0.00220.00230.0041
Pretty Stable
Revenue Per Share0.02540.02680.281
Slightly volatile
Interest Debt Per Share0.860.82330.3157
Slightly volatile
Debt To Assets0.760.72580.1413
Slightly volatile
Days Of Payables Outstanding1.9 K2 K7.3 K
Very volatile
Ebt Per Ebit0.780.880.9589
Slightly volatile
Long Term Debt To Capitalization0.620.80490.7435
Pretty Stable
Total Debt To Capitalization0.850.80650.1566
Slightly volatile
Debt Equity Ratio4.384.1680.7331
Slightly volatile
Quick Ratio17.079.097516.34
Slightly volatile
Net Income Per E B T1.11.131.0117
Slightly volatile
Cash Ratio2.963.11527.8369
Pretty Stable
Days Of Sales Outstanding1.3 K1.3 K264
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9851
Slightly volatile
Fixed Asset Turnover0.50.5212.3579
Slightly volatile
Debt Ratio0.760.72580.1413
Slightly volatile
Price Sales Ratio32.9764.5626.381
Slightly volatile
Asset Turnover0.01450.01530.1008
Slightly volatile
Gross Profit Margin0.720.810.8866
Slightly volatile

Milestone Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap252.6 M146.8 M289.6 M
Slightly volatile
Enterprise Value206 M176.3 M260.8 M
Slightly volatile

Milestone Fundamental Market Drivers

Cash And Short Term Investments69.7 M

Milestone Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Milestone Pharmaceuticals Financial Statements

Milestone Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Milestone Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Milestone Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Milestone Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue687.7 K722.1 K
Stock Based Compensation To Revenue 8.58  9.01 
Sales General And Administrative To Revenue 14.34  15.06 
Research And Ddevelopement To Revenue 27.95  29.34 
Capex To Revenue 0.10  0.07 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(70.26)(66.75)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Milestone Stock Analysis

When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY